combined targeted therapies in non-small cell lung cancer: a winner strategy?  current treatment modalities provide limited improvement in the natural course of lung cancer, and prognosis remains poor. lung cancer is a malignancy with great molecular heterogeneity. the complexity of the signalling process leading to cancer cell proliferation and to the neoplastic phenotype supports the necessity of interfering at different stages to avoid cancer cell resistance to therapy.